Fate Therapeutics, Inc. (FATE) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Fate Therapeutics, Inc. (FATE) closed at USD 1.94 on 2026-10-14, a change of +30.2 % over the past year, with a market capitalization of USD 230.65M.

Fate Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Fate Therapeutics, Inc. key figures

Previous close

USD 1.94 (2026-10-14)

1-year change

+30.2 %

Market cap

USD 230.65M

Enterprise value

USD 152.56M

P/E ratio (trailing)

-1.91

P/E ratio (forward)

-1.99

EPS (trailing)

-1.01

EPS (forward)

-0.97

PEG ratio

n/a

Price to book

1.46

Revenue growth

9.2 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.34

Employees

161

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Fate Therapeutics, Inc.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Fate Therapeutics, Inc. and compare it with other stocks.